Piramal Pharma completes acquisition of controlling stake in Yapan Bio to expand biologics CDMO capabilities
- nuaxia
- 2 giorni fa
- Tempo di lettura: 2 min
The acquisition makes Yapan Bio a Piramal Pharma subsidiary, strengthening the company's integrated biologics development and manufacturing offering for vaccines, biologics and antibody-drug conjugates.
Piramal Pharma has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited for ₹76 crore (approximately US$7.95 million), increasing its ownership to 74% and making the biologics CDMO a subsidiary.
The transaction expands Piramal Pharma Solutions' integrated large-molecule capabilities by adding Yapan Bio's expertise in biologics and vaccine development and manufacturing.
Field | Content |
Alert Type | Deal |
Companies | Piramal Pharma Limited; Yapan Bio Private Limited |
Deal Type | Acquisition of controlling stake |
Asset or Company | 74% controlling stake in Yapan Bio Private Limited |
Therapy Area(s) | Multiple |
Technology or Modality | Biologics and vaccine CDMO services; large-molecule development and manufacturing; antibody-drug conjugates (ADCs) |
Deal Value | ₹76 crore (approximately US$7.95 million) in cash for an additional 40.67% equity stake, increasing Piramal Pharma's ownership from 33.33% to 74%. (PR Newswire) |
Geography | India; Global |
What Happened | On 18 August 2026, Piramal Pharma completed its acquisition of an additional 40.67% stake in Hyderabad-based Yapan Bio, increasing its ownership to 74% and converting the company from an associate into a subsidiary. Piramal has held a strategic stake in Yapan Bio since 2021, and the completed transaction brings the company's biologics development and manufacturing capabilities fully into the Piramal Pharma Solutions CDMO business. (PR Newswire) |
Why It Matters | The acquisition expands Piramal Pharma Solutions' integrated biologics offering by adding specialist expertise in process development, characterisation and Phase I/II GMP manufacturing for vaccines and biologics. It also strengthens the company's ability to provide end-to-end large-molecule development services, including support for antibody-drug conjugate programmes. (PR Newswire) |
Supporting Context | Yapan Bio specialises in biologics and vaccine CDMO services and already supported Piramal Pharma Solutions' biologics offering following Piramal's initial investment in 2021. Integrating Yapan Bio as a subsidiary allows Piramal to embed these capabilities more fully into its global CDMO network. (PR Newswire) |
Strategic Rationale | Piramal gains greater operational control over a specialist biologics CDMO, enabling tighter integration of large-molecule development, manufacturing and ADC capabilities across its global service platform while supporting long-term expansion in biologics. (PR Newswire) |
Potential Impact | The acquisition could strengthen Piramal Pharma Solutions' competitive position in the growing biologics CDMO market by broadening its integrated service offering. The long-term commercial impact will depend on successful integration and continued demand for outsourced biologics manufacturing. (PR Newswire) |
Key Takeaway | By making Yapan Bio a subsidiary, Piramal Pharma strengthens its biologics CDMO platform and expands its ability to support customers developing complex large-molecule therapies. |
What to Watch | Integration of Yapan Bio into Piramal Pharma Solutions, expansion of biologics manufacturing services and continued development of the company's ADCelerate™ platform. (PR Newswire) |
Primary Source | |
Relevant Date | 18 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commenti